LGVN Longeveron

Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022

Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022

Live conference call on Monday, November 14 at 8:30 a.m. EST

MIAMI, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company’s financial results and provide a corporate update on the same day at 8:30 a.m. EST.

Dial-in Number

U.S. Dial-in Number: 844-200-6205

Canada Dial-in Number: 833-950-0062

All Other Locations Dial-in Number: 929-526-1599

Access code: 982246

U.S. Replay Dial-in Number: 866-813-9403

Canada Replay Dial-in Number: 226-828-7578

All Other Locations Dial-in Number: 44-204-525-0658

Conference ID: 329442

An audio webcast of the call may also be accessed from the ‘Investors’ page of the Longeveron website at . A replay of the call will be available on the Longeveron website shortly after completion of the call.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has a multi-modal mechanism of action that is pro-vascular, pro-regenerative, and anti-inflammatory, promoting tissue repair and healing with broad potential applications across a spectrum of disease areas. Longeveron is advancing Lomecel-B™ through clinical trials in three indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging Frailty. Additional information about the Company is available at .

Investor Contact:

Elsie Yau

Stern IR, Inc.

212-698-8700



EN
07/11/2022

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® to Attend BIO International Convention 2025

Longeveron® to Attend BIO International Convention 2025 Focus on potential partnership and strategic opportunities for the Company’s stem cell therapy program for Alzheimer’s diseaseRecent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2/3 clinical trial, which if positive, would be acceptable for Biological License Application (BLA) submission for Alzheimer’s diseaseInitiation of planned single, pivotal Phase 2/3 clinical trial in mild Alzheimer’s disease anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and/or partnering supportResults f...

May 20, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone ...

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapyStem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer’s disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selecte...

May 12, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Announces First Quarter 2025 Financial Results and Provide...

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer...

May 8, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® to Report First Quarter 2025 Financial Results and Host Co...

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: ...

May 2, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strat...

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 MIAMI, April 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders. Dear Fellow Shareholders, Twenty twenty-four was a year of execution for Longeveron. We made significant progress advancing Longeveron’s foun...

April 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch